Prot# 015-00: Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (MK-0683) (L-001079038) in Combination with Bortezomib in Patients With Advanced Multiple Myeloma

Project: Research project

Project Details

StatusFinished
Effective start/end date4/11/06 → 4/11/09

Funding

  • PRA Health Sciences (015-00)
  • Merck & Co., Inc. (015-00)